James Barclay and Barclay Capital Consult Sees Massive Success with Bet on French Biopharmaceutical Company Cellectis SA
Nov 2, 2023
Key Takeaways
- James Barclay and his private equity firm, Barclay Capital Consult, have been long-time supporters of Cellectis SA, a French biopharmaceutical company.
- Their faith and commitment to Cellectis SA have paid off, as the stock surged over 170% in Wednesday's trading session.
- Barclay's investment strategy, known as Event Driven Investing, focuses on capitalizing on specific events and catalysts to generate substantial returns.
- "I am delighted for my clients as well as my firm with these monumental profits we have shown," said James Barclay, expressing his excitement about the success.
- The success of their investment in Cellectis SA further solidifies Barclay Capital Consult's position as a leader in the private equity and event-driven investment sectors.
James Barclay, a seasoned investor, and his private equity firm, Barclay Capital Consult, have been longstanding supporters of Cellectis SA, a prominent French biopharmaceutical company.
London, England, United Kingdom - November 2, 2023 /PR Fire/ —
James Barclay, a seasoned investor, and his private equity firm, Barclay Capital Consult, have been longstanding supporters of Cellectis SA, a prominent French biopharmaceutical company. Their steadfast faith and commitment to Cellectis SA have yielded remarkable results, with the stock surging by over 170% in Wednesday's trading session. This monumental achievement is a testament to their investment strategy and deep-rooted belief in Event Driven Investing.
Event Driven Investing is an approach that capitalizes on specific events and catalysts to generate substantial returns on investment. James Barclay, the driving force behind this investment strategy, has dedicated years of hard work and expertise to bring these significant gains to his clients and firm. He expressed his excitement about this remarkable success, saying, "I am delighted for my clients as well as my firm with these monumental profits we have shown. I see Event Driven Investing as an art, and it comes through years of hard work. I would like to give thanks to my analysts in New York and also to my clients who have held their nerve and trusted my forecasts that this fantastic company would show us some serious percentage gains."
Cellectis SA, a leading player in the biopharmaceutical industry, is renowned for its innovative approaches to gene editing and cellular therapies. The recent surge in the company's stock price underscores the outstanding potential of Cellectis SA in the biopharmaceutical sector. James Barclay's foresight and astute investment decisions have been pivotal in realizing the company's potential.
Barclay Capital Consult has gained a reputation for its commitment to providing investors with exceptional opportunities in the market. The success of the Cellectis SA investment further cements the firm's position as a leader in the world of private equity and event-driven investments.
James Barclay and Barclay Capital Consult continue to pursue promising opportunities, demonstrating their dedication to delivering value and returns to their clients. Their investment in Cellectis SA serves as a shining example of the firm's commitment to identifying and capitalizing on transformative events in the market.
Contact Info:
Name: James Barclay
Email: Send Email
Organization: Barclay Capital Consult
Website: https://www.barclaycc.com
Source: PR Fire
Release ID: 89112165
In the event of detecting errors, concerns, or irregularities in the content shared in this press release that require attention or if there is a need for a press release takedown, we kindly request that you inform us promptly by contacting [email protected]. Our dedicated team will promptly address your feedback within 8 hours and take necessary actions to resolve any identified issues diligently or guide you through the removal process. Providing accurate and dependable information is our utmost priority.
More News
Squeeze into those skinny jeans: Millennial culture is back
A tech-powered 2000s revival represents the biggest nostalgia boom yet.
Slow Horses and Tenzing producer promises more underdog stories after French sale
Australian-British production company See-Saw Films has big plans after French entertainment giant Mediawan bought 51 per cent last year.
‘Final piece of the puzzle’: Western Sydney Airport opens for business
The first domestic Jetstar flight has departed Sydney’s new airport as the low-cost carrier bets big on Australia’s first new major airport in 50 years.
Big W has spent more than a decade in Kmart’s shadow. Can it pull off a comeback?
The discount retailer has been outpaced and outperformed by its much larger, more successful rival for years but is aiming for a turnaround.
‘Slow burn’: Western Sydney Airport’s real challenge awaits after launch
A lot of what happens next for Sydney’s newest airport depends on how much underlying demand is not being met by capacity-constrained Sydney Kingsford Smith.
The gym junkie tech boss whose company sustained a $3 billion wipeout
The fortunes of data centre business NextDC took a massive dive this week when its massive expansion plans hit a power pole in suburban Melbourne.
The prince’s bet on Trump is blowing up in his face
Saudi Arabia’s crown prince Mohammed bin Salman made a few big gambles as he rose to power, including one on Donald Trump.
ASX Runners of the Week: Energy Technologies, RAS Tech & Tambourah
The Bulls N’ Bears ASX Runner of the Week is… Energy Technologies, after it inked a potential US$10 million deal with an Israeli defence giant for its next-gen laser technology smart glasses.
Eddie McGuire no longer hosting a footy show on Nine
McGuire has been a central figure of AFL coverage on Nine for decades but won’t have an on-screen footy role for the network in 2027.
Cap Raise Crucible: Gold books, big fees and bruised punters
Argonaut led $225m of gold raisings; however, Wiluna plunged 22.3%. With eight of our ten featured stocks underwater, brokers’ fees and options stole the Cap Raise Crucible spotlight.
Big Hits: Rapid Critical Metals, Benz Mining, Encounter Resources
Big Hits looks at notable drill intercepts reported to the ASX this week, led by Rapid Critical Metals in NSW, with runners-up Benz Mining and Encounter Resources in WA.
‘Watch out, I’ll wait for you outside’: Aldi repealed self-serve checkout policy that fuelled abuse, threats
Aldi has repealed its policy of mandatory bag checks that became a lightning rod of frustration for shoppers and staff.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.